Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Breast Neoplasms 26Neoplasm Metastasis 5Endometrial Neoplasms 3Triple Negative Breast Neoplasms 2Recurrence 2Polycystic Ovary Syndrome 2Infertility 2Carcinoma, Intraductal, Noninfiltrating 2Breast Neoplasms, Male 2Advanced Breast Cancer 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sexual Dysfunctions, Psychological 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Leiomyoma 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1HR+/HER2- Breast Cancer 1HER2 Negative Breast Cancer 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Ductal 1Breast Neoplasm Female 1Breast Diseases 1Breast Carcinoma In Situ 1Anovulation 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

enzalutamide 21Magnetic Resonance Spectroscopy 21apalutamide 17Androgen Antagonists 14Specimen Handling 13Prednisone 13Abiraterone Acetate 13abiraterone 9Docetaxel 9Radiotherapy 8Biopsy 8darolutamide 7Radiosurgery 7Pluvicto 7Nivolumab 7cabazitaxel 6Lutetium-177 62-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6Lutetium 5radium Ra 223 dichloride 4pembrolizumab 4niraparib 4gallium 68 PSMA-11 4cabozantinib 4bicalutamide 4atezolizumab 4Watchful Waiting 4Surveys and Questionnaires 4Standard of Care 4Radiotherapy, Intensity-Modulated 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Letrozole × 30 days × Clear all
NCT07288359 2026-06-04

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Novartis

Phase 1/2 Recruiting
205 enrolled
BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡